

Drug (Sponsor)	Mechanism of Action/Target	CK18 Biomarker	Trial Phase	Length of Study	ClinicalTrials #
Alphalipoic acid (All India Institute of Medical Sciences)	antioxidant	CK18	4	12 weeks	NCT04475276
Berberine (FUDAN University)	AMPK Activation	CK18	4	48 weeks	NCT03198572
Metformin hydrochloride ER (Columbia University)	AMP activated Protein Kinase (AMPK) activator	M30 [®]	4	6 months	NCT02500147
Omega-3-acyl ethyl esters (University Hospital Southampton NHS Foundation Trust)	DGAT inhibitor	M30 [®]	4	18 months	NCT00760513
Pioglitazone hydrochloride (University of Florida)	PPAR-gamma activator	CK18	4	18 months	NCT00994682
Ademetionine (Abbott Labs)	Amino acids	CK18	3	7 weeks	NCT01754714
BIO-25 (Tel Aviv Sourasky Medical Center)	probiotic strains	CK18	3	6 months	NCT01922830
Diacein (Federal University of Rio de Janeiro)	Inhibits IL-1 beta production	CK18	3	24 months	NCT02242149
Diosmin (University of Tanta)	plant phlebotonic	CK18	3	3 months	NCT05942547
Hydroxytyrosol, alpha tocopherol (Bambino Gesu Paediatric Hospital)	antioxidant, vitamin E	CK18	3	4 months	NCT02842567
Oltipraz (PharmaKing Co)	AMPK pathway inhibitor	M30 [®] M65 [®]	3	24 weeks	NCT02068339, NCT04142749
Ubiquinol (University of Tanta)	CoA reductase inhibitor	CK18	3	12 weeks	NCT05731596
Vitamin E, metformin, or placebo (TONIC)	Combination	M30 [®]	3	96 weeks	NCT02499367
Vitamin E, pioglitazone, or placebo (PIVENS)	Combination	M30 [®]	3	96 weeks	NCT00063622
MGL-3196 / Resmetrom (Madrigal - MAESTRO-NASH)	THRbeta agonist	M30 [®]	2 & 3	36 weeks / 52 weeks	NCT04197479, NCT02912260
Obeticholic Acid (Intercept - REGENERATE)	FXR agonist	M30 [®] M65 [®]	2 & 3	24 weeks / 18 months	NCT02548351
Resveratrol (National Nutrition and Food Technology Research Institute)	stilbenoid, natural phenol	CK18	2 & 3	12 weeks	NCT02030977
Elafibranol (Genfit)	PPAR a/d agonist	M30 [®] M65 [®]	2b, 3	52 weeks	NCT02704403, NCT01694849, NCT03883607
Lanifibranol (Inventiva - NATIVE)	PanPPAR agonist	M30 [®]	2b & 3	24 weeks	NCT03008070
MSDC-0602K (Cirius)	MCP modulator	M30 [®]	2b & 3	26 weeks	NCT03970031, NCT02784444
Saroglitazar (Zydus Lifesciences)	dual PPAR α/γ agonist	M30 [®]	2b	76 weeks	NCT03061721, NCT05011305, NCT03617263
Tirzepatide (Eli Lilly)	GIP/GLP antagonist	M30 [®]	2b	26 weeks	
BI 1467335 (Boehringer Ingelheim)	VAP1 inhibitor	M30 [®] M65 [®]	2a	12 weeks	NCT03166735
PF-05221304 (Pfizer)	ACC 1/2 inhibitor	M30 [®] M65 [®]	2a	16 weeks	
TVB-2640 / Denifanstat (Sagimet - FASCINATE-1)	FASN inhibitor	M30 [®]	2a	12 weeks	NCT04906421, NCT03938246
BIO89-100 / Pegozafemin (89Bio)	FGF21	CK18	1b/2a		
ALS-L1023 (AngioLab Inc)	Herbal Extract	CK18	2	24 weeks	NCT04342793
ASP-9831 (Astellas Pharma)	PDE-4 Inhibitor	CK18	2	12 weeks	NCT00668070
Benecol (Maastricht University)	Plant Stanols	CK18	2 (N/A?)	12 months	NCT04783116
Betaine hydrochloride / Cystadane (Mayo Clinic)	methylating agent	CK18	2	1 year	NCT00586911
Bifidobacterium bifidum W23 + Bifidobacterium lactis W51 + Bifidobacterium lactis W52 + Lactococcus acidophilus W37 + Lactococcus brevis W63 + Lactococcus casei W56 + Lactococcus salivarius W24 + Lactococcus lactis W19 + Lactococcus lactis W58; berberine (Poznan University of Medical Sciences)	probiotic strains	CK18	2	12 weeks	NCT05523024
Bifidobacterium lactis + Lactobacillus acidophilus + Lactobacillus paracasei + Lactobacillus rhamnosus (Porto Alegre Clinical Hospital)	probiotic strains	CK18	2	24 weeks	NCT03467282
Cenicriviroc (Tobira Therapeutics Inc)	CCR2 and CCR5 pathway inhibitor	M30 [®] M65 [®]	2	24 weeks, 2 years	NCT02217475, NCT02330549
Chjglitazar sodium (Shenzhen Chipscreen Biosciences Co)	PPAR agonist	CK18	2	18 weeks	NCT05193916
Choline + curcumin + D-alpha-tocopherol + docosahexaenoic acid + phosphatidylcholine + silymarin (Neuromed - NUTRAFAST)	Combination	M30 [®]	2	3 months	NCT02369536
Cilofexor (Gilead)	FXR agonist	CK18	2	24 weeks	NCT02854605
Ciesacostat tromethamine; ervogastat (Pfizer)	ACC inhibitor / DGAT-2 inhibitor	CK18	2	12 weeks	NCT04399538
Docosahexaenoic acid; Quail-E (Indiana University)	omega-3 fatty acid, vitamins	CK18	2	6 months	NCT04198805
Empagliflozin (Ann & Robert H Lurie Children's Hospital of Chicago)	Sodium/Glucose Cotransporter 2 inhibitor	CK18	2	26 weeks	NCT03867487
Emricasan (Conatus/Histogen)	Pan-caspase inhibitor	M30 [®] M65 [®]	2	28 days, 24 weeks	NCT02077374, NCT02960204
Epanova / OM-3CA, Fenofibrate (AstraZeneca)	reduce triglyceride synthesis / PPARα agonist	M30 [®] M65 [®]	2	12 weeks	
Febuxostat (Tanta University)	Xanthine oxidase inhibitor	CK18	2	6 months	NCT05574036
Firsocostat/Cilofexor/Selonsertib (Gilead)	Combination	M30 [®] M65 [®]	2	12 weeks	NCT02781584
Firsocostat/Cilofexor/Semaglutide (Gilead - Novo Nordisk - ATLAS)	Combination	M30 [®] M65 [®]	2	24 weeks	NCT03987074
Foralumab (Tiziana Life Sciences Plc)	antagonist of CD3 antigen on the surface of T lymphocytes	CK18	2	60 days	NCT03291249
Huhuanguanlin (Tasly Holding Group Co)	Figwortflower Picrorhiza Rhizome	CK18	2	12 weeks	NCT05632861
Icosapent ethyl (Mochida Pharmaceutical)	DGAT Inhibitor, platelet aggregation inhibitor	CK18	2	1 year	NCT01154985
IMM-124E (Immuron)	Antibody, multifactorial	M65 [®]	2	12 weeks	NCT02316717
Lactobacillus brevis + Lactobacillus plantarum (AB-Biotics SA)	probiotic strains	CK18	2	4 months	NCT04823676
Leronlimab (Cytodyn Inc)	mAb against CCR5	CK18	2	92 days	NCT04521114
Leucine + Metformin hydrochloride + Sildenafil citrate (NuSirt BioPharma)	Combination	M30	2	112 days	NCT02546609
Liraglutide / Victoza (University of Birmingham)	GLP-1 receptor agonist	CK18	2	48 weeks	NCT01231719
Lisinopril (National Cancer Institute - RELIEF NAFLD)	C99AA ACE inhibitors	M30 [®]	2	24 weeks	NCT04550481
Losartan potassium (Emory University)	blocks binding of angiotensin II to AT1 receptor	CK18	2	22 weeks	NCT01913470
Maxicor (General University Hospital in Prague)	Nutrition-based Therapy	CK18	2	12 months	NCT02647294
MED10382 / Cotadutide (AstraZeneca)	GLP-1R/GCGR agonist	CK18	2		
Nivocasan (Gilead)	pan-caspase inhibitor	CK18	2	4 weeks	NCT00740610
Ozempic / Semaglutide (Novo Nordisk)	GLP1R agonist	M30 [®] M65 [®]	2	72 weeks	NCT02970942
Pegbelfermin (Bristol-Myers Squibb)	pegylated FGF21 analog	CK18	2	20 weeks, 24 weeks	NCT03486899, NCT02413372
Pemafibrate (Kowa Co)	PPAR-alpha agonist	CK18	2	72 weeks	NCT03350165
Pemafibrate + Tofogliflozin (Kowa Co)	PPAR-alpha agonist / SGLT-2 inhibitor	CK18	2	48 weeks	NCT05327127
Pioglitazone hydrochloride (Kaohsiung Medical University)	PPAR-gamma activator	CK18	2	9 months	NCT01068444
Px-104 (Phenex Pharmaceuticals)	FXR agonist	CK18	2	28 days	NCT01999101
Red ginseng (Chuncheon Sacred Heart Hospital)		M30 [®]	2	4 weeks	NCT03945123
Rencofilstat (Hepion Pharmaceuticals - ASCEND NASH)	cyclophilin A, cyclophilin B and cyclophilin D inhibitor	CK18	2	1 year	NCT05402371
Retatrutide (Eli Lilly)	GIP, GLP-1, and glucagon agonist	CK18	2	48 weeks	NCT04881760
Rifaximin (Mansoura University)	antibiotic	CK18	2	6 months	NCT02884037
Seladelpar (Cymabay)	PPAR delta agonist	M65 [®]	2	12 weeks	NCT03551522
Selonsertib (Gilead)	ASK-1 inhibitor	M30 [®] M65 [®]	2	24 weeks	NCT02466516
SNP-610 (Sinew Pharma)	DGAT2	CK18	2	12 weeks	NCT03468556
SNP-612 (Sinew Pharma)	multiple	CK18	2	3 months	NCT03868566
Survodutide / BI456906 (Boehringer Ingelheim)	glucagon receptor/GLP-1 receptor dual agonist	M30 [®]	2	60 weeks	NCT04771273
Tazarotene (GRI Bio)	RAR-beta and RAR-gamma dual agonist	CK18	2	28 days	NCT02949375
Tocopherol (Indiana University)	vitamin E	CK18	2	24 weeks	NCT03669133
Vitamin D3 (University of Zurich)	vitamin D	CK18	2	48 weeks	NCT01571063
AXA1125 (Axcella)	Metabolic modulator	M65 [®]	1	12 weeks	NCT04073368
Belapectin (Galectin Therapeutics)	Inhibitor of galectin-3	CK18	1	11 weeks	NCT01899859
DUR-928 (Durect)	Nuclear receptor modulator	M30 [®] M65 [®]	1	4 weeks	
TERN-201 (Terns Pharmaceuticals - AVIATION)	SSAO/VAP-1 inhibitor	CK18	1	12 weeks	NCT04897594
Anthocyanin (Shaoguan University)	plant flavonoid	M30 [®]	0	12 weeks	NCT01940263

Drug (Sponsor)	Mechanism of Action/Target	CK18 Biomarker	Trial Phase	Length of Study	ClinicalTrials #
Alphalipoic acid (All India Institute of Medical Sciences)	antioxidant	CK18	4	12 weeks	NCT04475276
BIO-25 (Tel Aviv Sourasky Medical Center)	probiotic strains	CK18	3	6 months	NCT01922830
Diosmin (University of Tanta)	plant phlebotonic	CK18	3	3 months	NCT05942547
Hydroxytyrosol, alpha tocopherol (Bambino Gesù Paediatric Hospital)	antioxidant, vitamin E	CK18	3	4 months	NCT02842567
Resveratrol (National Nutrition and Food Technology Research Institute)	stilbenoid, natural phenol	CK18	2 & 3	12 weeks	NCT02030977
ALS-L1023 (AngioLab Inc)	Herbal Extract	CK18	2	24 weeks	NCT04342793
Benecol (Maastricht University)	Plant Stanols	CK18	2	12 months	NCT04783116
Bifidobacterium bifidum W23 + Bifidobacterium lactis W51 + Bifidobacterium lactis W52 + Lactococcus acidophilus W37 + Lactococcus brevis W63 + Lactococcus casei W56 + Lactococcus salivarius W24 + Lactococcus lactis W19 + Lactococcus lactis W58; berberine (Poznan University of Medical Sciences)	probiotic strains	CK18	2	12 weeks	NCT05523024
Bifidobacterium lactis + Lactobacillus acidophilus + Lactobacillus paracasei + Lactobacillus rhamnosus (Porto Alegre Clinical Hospital)	probiotic strains	CK18	2	24 weeks	NCT03467282
Choline + curcumin + D-alpha-tocopherol + docosahexaenoic acid + phosphatidylcholine + silymarin (Neuromed - NUTRAFAST)	Combination	M30*	2	3 months	NCT02369536
Docosahexaenoic acid; Quali-E (Indiana University)	omega-3 fatty acid, vitamins	CK18	2	6 months	NCT04198805
Lactobacillus brevis + Lactobacillus plantarum (AB-Biotics SA)	probiotic strains	CK18	2	4 months	NCT04823676
Maxicor (General University Hospital in Prague)	Nutrition-based Therapy	CK18	2	12 months	NCT02647294
Tocopherol (Indiana University)	vitamin E	CK18	2	24 weeks	NCT03669133
Vitamin D3 (University of Zurich)	vitamin D	CK18	2	48 weeks	NCT01571063
Anthocyanin (Shaoguan University)	plant flavonoid	M30*	0	12 weeks	NCT01940263

cytokeratin-18 level >240 IU/L Inclusion criteria